Close Menu

Middle East

With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.

The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.

The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.

New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.